ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year
2024.06.27
Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance
2024.03.19
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024.03.18
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024.01.03
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2020-08-25
Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
2020-08-18
Essex Bio-Technology Reports First Half 2020 Financial Results
2020-08-10
Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech
2020-04-30
Essex Bio-Technology Joins X-ZELL Seed+ Investment Round
2020-03-17
FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination
2019-12-27
Preservative-free Single-dose rb-bFGF Eye Drops (Single-Dose Beifushu Eye Drops) Obtained Approval from NMPA for Commercialisation in China
2019-12-12
Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1
2019-08-21
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
<
3
4
5
6
7
8
9
>